[Federal Register Volume 60, Number 220 (Wednesday, November 15, 1995)]
[Notices]
[Page 57448]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-28150]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has made final findings of scientific misconduct in the following
case:
Weishu Y. Weiser, Ph.D., Harvard Medical School: On October 19,
1995, ORI found that Weishu Y. Weiser, Ph.D., formerly of the Harvard
Medical School at Brigham and Women's Hospital, committed scientific
misconduct by falsifying data in biomedical research supported by two
Public Health Service (PHS) grants.
Dr. Weiser has entered into a Voluntary Exclusion Agreement with
ORI in which she has accepted ORI's finding and has agreed to exclude
herself voluntarily, for the three (3) year period beginning October
19, 1995, from:
(1) Participating in any Federal contracts or subcontracts and from
eligibility for or involvement in Federal nonprocurement transactions
(e.g., grants and cooperative agreements), as covered in 45 C.F.R. Part
76 and 48 C.F.R. Subparts 9.4 and 309.4 (Debarment Regulations); and
(2) Serving in any advisory capacity to PHS, including but not
limited to service on any PHS advisory committee, board, and/or peer
review committee, or as a consultant.
She has agreed to submit a letter to the Journal of Immunology and
to the Proceedings of the National Academy of Sciences to retract the
articles entitled ``Human recombinant migration inhibitory factor
activates human macrophages to kill Leishmania donovani'' (Journal of
Immunology 147:2006-2011, 1991), ``Recombinant migration inhibitory
factor induces nitric oxide synthase in murine macrophages'' (Journal
of Immunology 150:1908-1912, 1993), and ``Recombinant human migration
inhibitory factor has adjuvant activity'' (Proceedings of the National
Academy of Sciences 89:8049-8052, 1992).
FOR FURTHER INFORMATION CONTACT: Director, Division of Research
Investigations, Office of Research Integrity, 5515 Security Lane, Suite
700, Rockville, MD 20852.
Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 95-28150 Filed 11-14-95; 8:45 am]
BILLING CODE 4160-17-P
